Technical Analysis for BLCM - Bellicum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 6.12 -2.24% -0.14
BLCM closed down 2.24 percent on Friday, September 21, 2018, on 2.12 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical BLCM trend table...

Date Alert Name Type % Chg
Sep 20 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.24%
Sep 20 Outside Day Range Expansion -2.24%
Sep 19 NR7 Range Contraction -3.77%
Sep 17 Oversold Stochastic Weakness -1.29%
Sep 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.16%
Sep 14 Stochastic Buy Signal Bullish -3.16%
Sep 14 Oversold Stochastic Weakness -3.16%
Sep 13 NR7 Range Contraction -0.65%
Sep 13 Inside Day Range Contraction -0.65%
Sep 13 Oversold Stochastic Weakness -0.65%

Older signals for BLCM ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of various forms of cancer. Its lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Its preclinical product candidates include BPX-401, a chimeric antigen receptor (CAR-T) product candidate for the treatment of hematological cancers that express the CD19 antigen; BPX-601, a CAR-T product candidate for treating solid tumors overexpressing the prostate stem cell antigen; and BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Is BLCM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.22
52 Week Low 5.02
Average Volume 412,339
200-Day Moving Average 7.5109
50-Day Moving Average 6.6005
20-Day Moving Average 6.5575
10-Day Moving Average 6.21
Average True Range 0.313
ADX 14.96
+DI 18.6489
-DI 26.9102
Chandelier Exit (Long, 3 ATRs ) 6.321
Chandelier Exit (Short, 3 ATRs ) 6.839
Upper Bollinger Band 7.4073
Lower Bollinger Band 5.7077
Percent B (%b) 0.24
BandWidth 25.918414
MACD Line -0.1524
MACD Signal Line -0.131
MACD Histogram -0.0214
Fundamentals Value
Market Cap 203.34 Million
Num Shares 33.2 Million
EPS -2.94
Price-to-Earnings (P/E) Ratio -2.08
Price-to-Sales 975.18
Price-to-Book 2.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.74
Resistance 3 (R3) 6.73 6.52 6.63
Resistance 2 (R2) 6.52 6.36 6.52 6.60
Resistance 1 (R1) 6.32 6.27 6.22 6.33 6.56
Pivot Point 6.11 6.11 6.06 6.11 6.11
Support 1 (S1) 5.91 5.95 5.81 5.92 5.68
Support 2 (S2) 5.70 5.86 5.70 5.64
Support 3 (S3) 5.50 5.70 5.61
Support 4 (S4) 5.51